Regulatory shifts and the limitations of traditional solutions have increased the need for physiologically complex in vitro models. Bioprinting enables high spatial control, automation, and scalability, yet its adoption into preclinical workflows has been severely hindered by logistical constraints, particularly the extremely limited shelf-life of the bioprinted models. To address this, we developed a cryobioprinting strategy that integrates in situ freezing with bioprinting to preserve the models during fabrication, thus extending their shelf-life. Furthermore, we have developed proprietary hardware and biomaterials which enable us reduce print-times from >30 minutes to just ~2 minutes all while maintaining cell functionality even after months of storage, a capability that cannot be achieved with conventional bioprinting techniques. In doing so, we have developed a technology that enables pharma and biotech companies to have >80% faster assay start with a more physiologically relevant model; thus, enabling faster and more effective translation from preclinical to clinical trials. We aim to provide the audience with a technical undersating of the world of bioprinting (and its broad applications and impacts) and a glimpse into an new and transformative biofabrication technology called cryobioprinting.
Learning Objectives:
Gain deep technical insights and understand the impacts of cryobioprinting, a new and transformative biofabrication technology.
Describe and define the broad applications that 3D printing has in other fields, specifically in tissue engineering, regenerative medicine, and preclinical drug development.
Understand the foundational concepts of bioprinting, such as: the materials, processes, and applications.
